california
molecular
test
use
decreas
suspicion
sever
acut
respiratori
syndrom
sar
detect
common
respiratori
pathogen
influenza
ab
human
metapneumoviru
picornaviru
mycoplasma
pneumonia
chlamydia
spp
parainfluenza
viru
respiratori
syncyti
viru
adenoviru
patient
suspect
sar
patient
probabl
sar
ever
acut
respiratori
syndrom
sar
becom
new
paradigm
global
havoc
produc
emerg
infecti
diseas
juli
total
probabl
sar
case
report
world
health
organ
countri
area
death
casefat
ratio
california
particularli
affect
sar
outbreak
report
one
fifth
suspect
probabl
case
unit
state
suspect
sar
case
probabl
sar
case
two
serolog
confirm
case
california
unexplain
pneumonia
cup
project
respiratori
surveil
project
use
enhanc
laboratori
techniqu
identifi
etiolog
agent
sever
pneumonia
initi
california
depart
health
servic
cdh
collabor
center
diseas
control
prevent
cdc
emerg
infect
program
cup
project
extens
diagnost
test
algorithm
appli
specimen
submit
cdh
sar
test
march
juli
case
possibl
sar
report
cdh
classifi
suspect
probabl
laboratoryconfirm
accord
cdc
criteria
extens
diagnost
test
perform
cdh
viral
rickettsi
diseas
laboratori
specimen
patient
includ
condit
meet
strict
cdc
case
criteria
tabl
submit
specimen
transport
cold
pack
either
frozen
process
immedi
total
respiratori
specimen
serum
specimen
analyz
includ
nasopharyng
swab
nasal
swab
throat
swab
nasal
wash
sputum
specimen
endotrach
aspir
singl
acutephas
serum
specimen
acuteand
convalescentphas
pair
serum
specimen
convalescentphas
serum
specimen
collect
least
day
symptom
onset
difficulti
obtain
convalescentphas
sera
specimen
casepati
underw
combin
test
polymeras
chain
reaction
pcr
cultur
serolog
method
total
nucleic
acid
extract
respiratori
specimen
revers
transcriptas
rt
pcr
use
masterpur
complet
dna
rna
purif
kit
epicentr
technolog
madison
wi
rtpcr
assay
perform
accord
erdman
et
al
primer
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
type
influenza
b
piv
coronaviru
cov
revers
primer
human
metapneumoviru
hmpv
primer
cov
cov
forward
primer
modifi
myint
et
al
use
adenoviru
picornaviru
primer
adenoviru
forward
primer
ac
tt
ct
aaccaccaccg
revers
gct
c
gt
ga
agttcca
picornaviru
forward
primer
ct
revers
reaction
product
visual
ethidium
bromidestain
agaros
gel
ultraviolet
illumin
rtpcr
sarscov
perform
icycl
biorad
laboratori
inc
hercul
ca
use
taqman
onestep
rtpcr
master
mix
appli
biosystem
foster
citi
ca
primer
probe
develop
cdc
base
gene
amplif
specimen
patient
suitabl
molecular
test
rtpcr
detect
respiratori
pathogen
tabl
patient
one
agent
identifi
molecular
method
addit
respiratori
sampl
adequ
volum
ad
vero
primari
rhesu
monkey
kidney
cell
human
fetal
diploid
lung
cell
accord
standard
diagnost
procedur
virus
isol
patient
tabl
specimen
yield
posit
viral
cultur
also
posit
rtpcr
overal
rtpcr
assay
sensit
cultur
exampl
patient
influenza
detect
rtpcr
cultureposit
serolog
test
perform
specimen
patient
tabl
signific
rise
immunoglobulin
ig
g
seen
patient
pair
acuteand
convalescentphas
serum
specimen
pneumonia
patient
influenza
patient
chlamydia
spp
rsv
influenza
b
adenoviru
patient
singl
serum
sampl
collect
two
patient
detect
igm
one
chlamydia
spp
pneumonia
patient
pneumonia
also
influenza
detect
pcr
cultur
patient
one
evid
possibl
coinfect
seven
put
causal
agent
identifi
serolog
test
alon
without
correspond
posit
find
pcr
cultur
includ
one
influenza
influenza
b
rsv
adenoviru
pcr
assay
perform
retrospect
specimen
patient
posit
serolog
result
pneumonia
chlamydia
spp
neg
organ
specimen
addit
two
patient
show
rise
igg
multipl
antigen
consist
nonspecif
immun
respons
respiratori
specimen
posit
sarscov
rtpcr
although
serolog
test
sampl
two
patient
posit
sarscov
antibodi
sequenc
analys
confirm
ident
hmpv
influenza
rtpcr
amplif
product
blast
avail
wwwncbihlmnihgovblast
comparison
five
put
hmpv
specimen
show
ident
hmpv
sequenc
genbank
similarli
influenza
amplif
product
patient
identifi
sole
rtpcr
show
homolog
known
influenza
virus
patient
test
met
criteria
suspect
sar
met
criteria
probabl
sar
serolog
confirm
sar
tabl
like
pathogen
detect
suspect
probabl
sar
patient
march
juli
california
report
patient
met
criteria
suspect
probabl
sar
state
mani
emerg
room
hospit
public
health
offic
overwhelm
hundr
person
evalu
local
counti
report
cdh
classifi
suspect
probabl
sar
patient
onethird
pathogen
detect
consid
like
caus
condit
base
clinic
featur
cours
ill
twentyon
pathogen
identifi
rtpcr
within
averag
day
california
determin
commonli
recogn
caus
influenzalik
ill
allow
case
remov
suspect
probabl
sar
categori
result
remov
sar
design
allevi
requir
epidemiolog
investig
hospit
isol
strict
infect
control
precaut
addit
specimen
collect
contact
trace
although
viral
bacteri
coinfect
sar
remain
possibl
sarscovinfect
casepati
worldwid
document
evid
dual
infect
includ
c
pneumonia
pneumonia
hmpv
case
report
laboratoryconfirm
sar
noteworthi
lack
viral
agent
accordingli
sar
rule
common
culprit
viral
pathogen
detect
area
without
known
commun
transmiss
sar
howev
sever
factor
consid
discontinu
evalu
possibl
sar
like
altern
caus
identifi
includ
follow
strength
epidemiolog
link
sar
specif
diagnost
test
perform
clinic
featur
cours
ill
altern
diagnosi
sar
becom
reestablish
exclus
criteria
may
need
reevalu
appli
particular
caution
patient
strong
epidemiolog
exposur
context
commun
transmiss
appli
molecular
techniqu
outbreak
investig
rel
recent
approach
limit
molecular
test
includ
possibl
falseposit
result
caus
specimen
contamin
process
falseneg
result
primer
mismatch
inhibitor
specimen
ideal
diagnost
set
posit
result
molecular
techniqu
confirm
either
test
anoth
specimen
method
specimen
anoth
method
immunoassay
cultur
also
detect
agent
pcr
alway
indic
true
caus
infect
may
instead
signifi
nasopharyng
carriag
simpli
innoc
bystand
nevertheless
given
nonspecif
initi
sign
symptom
patient
sar
capac
rapidli
diagnos
common
respiratori
infect
use
sensit
pcr
method
offer
advantag
context
respiratori
outbreak
found
appli
broad
diagnost
molecular
panel
sar
outbreak
enabl
time
identif
agent
common
respiratori
viral
infect
one
third
patient
suspect
probabl
sar
case
although
serolog
test
aid
identif
select
atyp
pathogen
requir
pair
serum
specimen
allow
time
remov
sar
design
even
rapid
definit
diagnost
test
sar
becom
avail
laboratori
capabl
perform
molecularbas
diagnost
test
especi
influenza
maintain
strengthen
